An official website of the United States government

Citation
Belle, Steven (2022). Pediatric Acute Liver Failure (PALF) (Version 2) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/hbe8-s748
Data Availability Statement
Data from the Pediatric Acute Liver Failure (PALF) [(Version 2) https://doi.org/10.58020/hbe8-s748] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.
Acknowledgement Statement
The PALF study was conducted by the study investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The resources from the PALF (https://doi.org/10.58020/hbe8-s748) study reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the PALF study and does not necessarily reflect the opinions or views of the PALF study, NIDDK-CR, or NIDDK.
Data Package Version
Version 2 (Updated on: Feb 17, 2022)
Resource Availability
  • Data Available for Request
  • Specimens Available for Request
Publications
Explore publications resulting from the use of study resource
View publications (4)

General Description

Acute liver failure (ALF) is a condition in which liver function rapidly deteriorates. ALF often affects young people and causes serious, and sometimes fatal, complications. Treatment of the disease is dependent upon its cause, which can be numerous factors. Because recovery from this disease is random, there is no way to predict how a patient will respond to treatment. Sometimes a liver transplant is required in order for a patient to make a full recovery. The mission of the Pediatric Acute Liver Failure (PALF) study is to develop methods to predict whether a child will require a life-saving procedure in order to recover from the illness.

Clinical, epidemiological, and outcome data on PALF patients will be collected and analyzed. The study group will also use the data to identify unrecognized mechanisms of liver injury that cause PALF. Acute liver failure leads to hepatic encephalopathy and cerebral edema, so patients will be invited to participate in neurocognitive testing to determine whether long-term neurocognitive function has been compromised. The prediction methods will vary and be influenced by age, diagnosis, multi-system organ failure, degree of encephalopathy, and coagulopathy level.

Objectives

The objective of the PALF study is to gather information on children with acute liver failure (ALF). The data will be used to develop methods to predict whether a child will require a life-saving procedure in order to recover from the illness.

Outcome Measure

Primary Outcome Measure: Biospecimens and various data on children with acute liver failure will be collected and analyzed.

Secondary Outcome Measure: The outcome of the neurocognitive testing will be evaluated.

Eligibility Criteria

Inclusion: Participants of this study must be age 17 or younger; have diagnosed acute liver injury; and have untreated coagulopathy.

Exclusion: Individuals will be excluded from the study if they have chronic liver disease; are an organ or bone marrow transplant recipient; experienced multi-organ system failure after heart surgery or ECMO; or suffered acute trauma.

Outcome

This study is completed.

Research Area

Liver Disease

Study Type

Observational

Study Sites

12

Study Start Date

2000-01

Study End Date

2015-12

Condition

Hepatic Encephalopathy, Acute Liver Failure

Keywords

Acute Liver Failure, Untreated Coagulopathy, Hepatic Encephalopathy

NIDDK Division

Division of Digestive Diseases and Nutrition

468
Participants

Target Population
Children
Location statistics is not available for this study

Public Documents Table
Document Name
Description
Document Type
File Format
Compliance
Download

Non-Public Documents (1)
Non-Public Documents Table
Document Name
Description
Document Type
File Format
Datasets (70)
Datasets Table
Dataset Name
Description
# of Records
# of Variables
File Format(s)
Specimens (27,374)
Specimens Table
Specimen
Count
BILE123
Cells260
DNA2202
Dried Blood Spot296
EBV Transformed Cell Lines2030
Fibroblasts/skin165
Fibroblasts/tendon5
Liver Tissue1848
Lymphocytes164
Plasma6405
Plasma or Serum18
Serum13011
Urine847